Presentation is loading. Please wait.

Presentation is loading. Please wait.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Published byCatherine Harper Modified over 5 years ago

Similar presentations

Presentation on theme: "Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al"— Presentation transcript:

1 Feasibility of Lenalidomide Maintenance After ASCT in Patients With Multiple Myeloma
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med ;366: This program is supported by educational grants from

2 Background Autologous hematopoietic stem cell transplantation (ASCT) after induction chemotherapy for MM improves responses and consolidates CR[1] Maintenance therapy given to prevent relapse, prolong CR Thalidomide maintenance after ASCT improves PFS, OS, but limited by toxicity[2] Lenalidomide: oral immune-modulating agent active against MM Favorable toxicity profile ASCT, autologous hematopoietic stem cell transplantation; CR, complete response; OS, overall survival; PFS, progression-free survival; MM, multiple myeloma 1. Palumbo A., et al. N Engl J Med. 2011;364: Morgan GJ, et al. Blood. 2012;119:7-15

3 Lenalidomide Maintenance After ASCT
Stratified by β2-microglobulin level at registration, type of induction therapy Induction of melphalan maintenance therapy between Days Lenalidomide 10 mg/d (n = 135) Restage on Days , then randomize Patients symptomatic, stage I-III MM with ≥SD following ≤2 cycles of induction and adequate stem cells (N = 568) Single ASCT CR, PR, SD Placebo (n = 229) ASCT, autologous stem cell transplantation; CR, complete response; OS, overall survival; PR, partial response; SD, stable disease; TTP, time to progression Primary endpoint: TTP following ASCT Secondary endpoints: OS, overall response, safety McCarthy PL, et al., N Engl J Med. 2012;366:

4 TTP, EFS, and OS With Lenalidomide Maintenance
Outcome Lenalidomide (n = 231) Placebo (n = 229) Median EFS (mo.) 43 27 Median TTP (mo.) 46 Combined PD, death, and SPM 40% 58% Deaths 15% 23% Response after ASCT 60 Lenalidomide 50 Placebo 40 Patients (%) Improved OS at 3 years in lenalidomide arm (P = .03) EFS = PD + death + SPM Post-hoc endpoint to assess influence of SPM on outcomes Lenalidomide reduced risk of event 47% (HR = 0.53 (95% CI, ) 30 ASCT, autologous stem cell transplantation; CR, complete response; EFS, event-free survival; MR, minimal response; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease; SPM, second primary malignancy; TTP, time to progression 20 10 CR PR MR SD PD McCarthy PL, et al., N Engl J Med. 2012;366:

5 Lenalidomide Maintenance After ASCT: Risk Stratification and Outcomes
Reduction in risk of death or PD Fewer events in lenalidomide (37%) vs placebo (58%) Fewer deaths in lenalidomide (15%) vs placebo (23%) TTP by stratification factors Trend to superiority of lenalidomide induction vs no lenalidomide induction (P value for interaction = .06) No significant difference in TTP for thalidomide induction vs no thalidomide induction OS by stratification factors Lenalidomide induction superior to no lenalidomide (P = .03) Thalidomide induction inferior to no thalidomide (P = .05) CR, complete response; OS, overall survival; PD, progressive disease; OS, overall survival; TTP, time to progression McCarthy PL, et al., N Engl J Med. 2012;366:

6 Adverse Events Associated with Lenalidomide Maintenance After ASCT
Grade 3/4 Hematologic AEs (%) Lenalidomide (n = 231) Placebo (n = 229) P Value Any event 48 17 < .001 Neutropenia 45 15 Thrombocytopenia 14 4 0.001 Lymphopenia 6 1 0.01 Anemia 5 0.006 Leukocytopenia 11 3 AE, adverse event; ASCT, autologous stem cell transplantation McCarthy PL, et al., N Engl J Med. 2012;366:

7 Lenalidomide Maintenance After ASCT: Second Primary Malignancies
Outcome Lenalidomide (n = 231) Placebo (n = 229) Second primary cancer, % 8 3 Second primary hematologic cancers, n 1 AML, ALL, MDS, Hodgkin lymphoma non-Hodgkin lymphoma Second primary solid tumors, n 10 5 breast, gastrointestinal, malignant melanoma, gynecologic, central nervous system, thyroid, prostate gastrointestinal, malignant melanoma, gynecologic, carcinoid Risk of SPM higher with lenalidomide (P = .008) Risk of PD higher in placebo group (P < .001) Risk of death higher in placebo group (P = .002) 47% reduction in risk of EFS event (death, SPM, or PD) (HR = 0.53, 95% CI, ) in lenalidomide arm ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; EFS, event-free survival; MDS, myelodysplastic syndrome; PD, progressive disease; SPM, second primary malignancy McCarthy PL, et al., N Engl J Med. 2012;366:

8 Lenalidomide Maintenance After ASCT: Summary of Results
Lenalidomide maintenance therapy feasible for long-term administration after ASCT in patients with multiple myeloma Significantly improved OS and TTP Significantly more grade 3/4 hematologic adverse events with lenalidomide vs placebo In post hoc analysis, lenalidomide maintenance still superior in EFS despite increased incidence of SPM in lenalidomide arm Patients should be carefully monitored when using this approach Further study needed to determine if additional agents combined with lenalidomide may provide further survival benefit ASCT, autologous stem cell transplantation; OS, overall survival; TTP, time to progression McCarthy PL, et al., N Engl J Med. 2012;366:

Download ppt "Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al"

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Palumbo A et al. Proc ASH 2013;Abstract 536.
Treatment For Newly Diagnosed Myeloma

Treatment For Newly Diagnosed Myeloma
Facon T et al. Proc ASH 2013;Abstract 2.

Facon T et al. Proc ASH 2013;Abstract 2.
1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.
Palumbo A et al. Proc ASH 2012;Abstract 446.

Palumbo A et al. Proc ASH 2012;Abstract 446.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.

Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.
Sergio Giralt defends the PRO position To Maintain or Not to Maintain The Answer is Yes And Lenalidomide is the Right Choice.

Sergio Giralt defends the PRO position To Maintain or Not to Maintain The Answer is Yes And Lenalidomide is the Right Choice.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

Similar presentations

Ads by Google